Saudi Central Bank Raises Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Saudi Central Bank boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 85.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,550 shares of the medical equipment provider’s stock after purchasing an additional 6,235 shares during the quarter. Saudi Central Bank’s holdings in Zimmer Biomet were worth $1,167,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the company. DV Equities LLC bought a new position in shares of Zimmer Biomet in the fourth quarter worth $25,000. Tacita Capital Inc bought a new stake in Zimmer Biomet during the second quarter valued at $26,000. Ancora Advisors LLC purchased a new position in Zimmer Biomet during the second quarter worth about $29,000. Monetary Solutions Ltd bought a new position in Zimmer Biomet in the 4th quarter worth about $30,000. Finally, Gen Wealth Partners Inc bought a new position in Zimmer Biomet in the 4th quarter worth about $31,000. 88.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ZBH shares. Canaccord Genuity Group lifted their price target on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research report on Monday, August 10th. Zacks Research upgraded shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. Royal Bank Of Canada boosted their price target on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $96.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $104.42.

Zimmer Biomet Stock Down 4.1%

Shares of NYSE:ZBH opened at $94.10 on Wednesday. The stock has a market capitalization of $17.95 billion, a P/E ratio of 22.89, a price-to-earnings-growth ratio of 1.85 and a beta of 0.47. The stock’s 50-day moving average price is $95.12 and its 200-day moving average price is $91.59. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $106.88.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06. The company had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.Zimmer Biomet’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the business posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.